Aprea Therapeutics APRE 深 滬
等待開盤 12-20 09:30:00 美东时间
0.921
+0.011
+1.20%
華盛通- 最 高0.93
- 今 開0.93
- 成交量 4.48万股
- 最 低 0.9055
- 昨 收 0.9101
- 總市值 581.22万
- 52周最高 5.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.90
- 委 比 94.53%
- 總股本 631.07万
- 歷史最高 1062.20
- 量 比 2.00
- 振 幅 2.69%
- 歷史最低 0.90
- 每 手 1
- 風險率 0.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aprea Therapeutics Updates 2025 Progress, Cash Runway To Support Operations Through Q1 2027
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that target weaknesses in cancer cells while minimizing damage to healthy
12-18 21:39
Aprea Therapeutics Enters $3.1M Securities Purchase Agreement Through Sale Of 2,623,023 Shares And Warrants At A Combined Price Of $1.165
Financing from new and existing healthcare focused investorsThe proceeds are expected to extend the Company's cash runway into Q1 2027, with potential inflection points anticipated in its clinical programs during that
12-09 21:38
Aprea Therapeutics Q3 EPS $(0.47) Misses $(0.34) Estimate
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.34) by 38.24 percent. This is a 26.56 percent increase over losses of $(0.64) per share
11-12 21:40
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors
Aprea Therapeutics, Inc. (($APRE)) announced an update on their ongoing clinica...
10-28 01:27
Aprea To Feature Preliminary Results From ACESOT-1051 Trial Through September 17 In Poster Presentation At AACR-NCI-EORTC
3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors
10-24 20:35
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
<p>Aprea Therapeutics reported early results from its Phase 1 ACESOT-1051 trial, showing that 75% of heavily pretreated gastrointestinal and gynecologic cancer patients achieved stable disease at the 100 mg dose of APR-1051, its WEE1 kinase inhibitor. Disease stabilization was observed in tumors with mutations relevant to WEE1 inhibition, including FBXW7, CCNE1, KRAS G12V, and TP53. Dose escalation continues, with patients now enrolling in the 15...
10-24 12:30
Aprea Therapeutics Shifts Focus to Combination Therapies
Aprea Therapeutics ( ($APRE) ) has shared an announcement. On October 15, 2025,...
10-15 20:27
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
Aprea Therapeutics identified the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119, an oral ATR inhibitor, in the monotherapy arm of its ABOYA-119 Phase 1/2a study for patients with advanced solid tumors. The company is pausing further enrollment in monotherapy arms to focus on strategic high-value combinations, such as DNA-damaging agents and immune checkpoint inhibitors, based on preclinical data suggesting synergistic anti-tumor ef...
10-15 12:00
Aprea Therapeutics Announces Two Abstracts On Clinical Programs, APR-1051 And ATRN-119, Accepted For Poster Presentation At EORTC-NCI-AACR International Conference
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to
10-14 20:03
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
Aprea Therapeutics announced that two abstracts for its clinical programs, APR-1051 and ATRN-119, have been accepted for poster presentations at the EORTC-NCI-AACR conference in Boston. Both presentations will occur on October 24th during Poster Session B in Exhibit Hall D. APR-1051 is a WEE1 inhibitor targeting cancer-associated gene alterations, while ATRN-119 is an ATR inhibitor for advanced solid tumors with DNA damage. The posters will be av...
10-14 12:00
